Pediatric Anticoagulation: Who, What, When, Where, and Why (and a little How) (225)

11:00 am – 12:00 pm Saturday, September 17

Pediatric anticoagulation can present challenges to the advanced practice nurse (as well as the ambulatory or bedside nurse) with limited experience in the broad scope of clinical scenarios where either prophylactic or treatment anticoagulation is recommended (it's not just clots). Traditionally, the only pharmacologic options utilized in children have been limited to heparin (including low molecular weight heparin) and warfarin. However, direct oral anticoagulants (DOACs) are now being incorporated in a limited fashion, dependent on both age of the child and clinical application.

This concurrent session will provide an overview of current practice trends and recommendations in pediatric anticoagulation with an emphasis on specific clinical scenarios including transient and static hypercoagulable states (e.g., renal disease, complex congenital cardiac disease, artificial cardiac valves, severe COVID19 illness/MIS-C), VTE prophylaxis versus treatment, and choice of agent in the context of both inpatient and ambulatory care. Ambulatory care coordination for this oft-complex patient population will be discussed, and Joint Commission requirements for anticoagulation monitoring and education will also be reviewed. Finally, case study review and discussion will elucidate common and unusual concepts encountered in clinical practice.

Tagged under

Related items